4945-46-4

Basic information

• Product Name: 6-(1-piperidinyl)-2-Pyridinamine
• Synonyms: 6-(1-piperidinyl)-2-Pyridinamine;6-(Piperidin-1-yl)pyridin-2-amine;6-(1-piperidinyl)-2-pyridinylamine
• CAS NO: 4945-46-4
• Molecular Formula: C₁₀H₁₅N₃
• Molecular Weight: 177.2462
• Mol File: 4945-46-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-(1-piperidinyl)-2-Pyridinamine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(1-piperidinyl)-2-Pyridinamine(4945-46-4)
• EPA Substance Registry System: 6-(1-piperidinyl)-2-Pyridinamine(4945-46-4)

Safety Data

• Hazardous Substances Data: 4945-46-4(Hazardous Substances Data)

Upstream product

• 110-89-4 piperidine 
• 1597-32-6 6-fluoro-pyridin-2-ylamine 
• 19798-81-3 2-Amino-6-bromopyridine 
• 110-86-1 pyridine 

Downstream Products

• 1415380-82-3 6-phenyl-N-(6-(piperidin-1-yl)pyridin-2-yl)imidazo[1,2-b]pyridazin-8-amine 
• 1431772-53-0 6-phenyl-N-(6-(piperidin-1-yl)pyridin-2-yl)imidazo[1,2-b]pyridazin-8-amine hydrochloride 

Relevant articles and documents

A practical synthesis of substituted 2,6-diaminopyridines via microwave-assisted copper-catalyzed amination of halopyridines

A microwave assisted copper-catalyzed amination protocol is reported utilizing a series of 2,6-dihalo- and 2-amino-6-halo pyridine precursors. Using this procedure, selective substitution of one or two halogens by aryl or alkylamines was achieved within 2-6 h with temperatures between 80 and 225 °C affording 2,6-diaminopyridines in good to excellent isolated yields. The reaction allows easy variation between educts and different N-substitutions. The target compounds are valuable precursors for the synthesis of bis-phosphorylated 2,6-diaminopyridines which are used as PNP pincer ligands in transition metal complexes.

IMIDAZOPYRIDAZINE COMPOUNDS

The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Rational design of highly selective spleen tyrosine kinase inhibitors

A novel approach to design selective spleen tyrosine kinase (Syk) inhibitors is described. Inhibition of spleen tyrosine kinase has attracted much attention as a mechanism for the treatment of autoimmune diseases such as asthma, rheumatoid arthritis, and SLE. Fostamatinib, a Syk inhibitor that successfully completed phase II clinical trials, also exhibits some undesirable side effects. More selective Syk inhibitors could offer safer, alternative treatments. Through a systematic evaluation of the kinome, we identified Pro455 and Asn457 in the Syk ATP binding site as a rare combination among sequence aligned kinases and hypothesized that optimizing the interaction between them and a Syk inhibitor molecule would impart high selectivity for Syk over other kinases. We report the structure-guided identification of three series of selective spleen tyrosine kinase inhibitors that support our hypothesis and offer useful guidance to other researchers in the field.